Jefferies Virtual London Healthcare Conference

November 17-18, 2020
Forward-Looking Statements and Non-GAAP Financial Measures

FORWARD-LOOKING STATEMENTS

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the “Company”), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products, and plans or objectives related to the Operational Excellence Program, (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program, (iii) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including the scope and duration of the outbreak, government actions and restrictive measures implemented in response, availability and demand for the Company’s products, and our ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; the impact of share repurchases on our stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness; technological advances in the medical field and standards for transfusion medicine and our ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.

MANAGEMENT’S USE OF NON-GAAP MEASURES

This presentation contains financial measures which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. In this presentation, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in our underlying businesses. We strongly encourage investors to review our financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. When used in this presentation, organic revenue growth excludes the impact of currency fluctuation, product end-of-life activities, strategic exits of product lines and divestitures. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. Reconciliations of these measures to their most comparable GAAP measures are included in the Company’s earnings release for the fourth quarter fiscal 2020 dated May 5, 2020, which is available on the Company’s website: www.haemonetics.com.
Global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.
Long-term value creation strategy that is supported by multiple value drivers

Corporate Strategy

Compete in winning segments and geographies

Achieve leading position in each segment where we compete

Deliver superior short-term and long-term operating performance (ROIC)

Value drivers

1. Plasma market
2. Hospital market
3. Mergers & Acquisitions
4. Innovation Agenda
5. Operational Excellence
6. Capital Allocation
FY20 revenue snapshot in the customer-centric business unit structure

**FY20 Revenue**

<table>
<thead>
<tr>
<th>Category</th>
<th>% Revenue ex. NA¹</th>
<th>% Disp. revenue²</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA¹</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>% Disp. revenue²</td>
<td>92%</td>
<td></td>
</tr>
<tr>
<td>% NA disp. revenue (excluding solutions)³</td>
<td>78%</td>
<td></td>
</tr>
<tr>
<td><strong>Hospital</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA¹</td>
<td>43%</td>
<td></td>
</tr>
<tr>
<td>% Disp. revenue²</td>
<td>70%</td>
<td></td>
</tr>
<tr>
<td>% HM⁴ revenue</td>
<td>48%</td>
<td></td>
</tr>
<tr>
<td><strong>Blood Center</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA¹</td>
<td>68%</td>
<td></td>
</tr>
<tr>
<td>% Disp. revenue²</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td><strong>Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA¹</td>
<td>55%</td>
<td></td>
</tr>
</tbody>
</table>

1. Revenue excluding North America
2. Disposables revenue
3. North America (NA) disposables revenue excluding liquid solutions
4. Hemostasis Management/ TEG

Fiscal 2020 revenue percentages do not reflect the impact of certain strategic exits of product lines, acquisitions and divestitures that occurred in fiscal 2021. For more information please refer to Haemonetics’ Form 10-Q for the second quarter ended September 26, 2020 as filed with the SEC, as well as the Company’s earnings release and analytical tables and supplemental information for the second quarter available at [https://haemonetics.gcs-web.com/investor-overview](https://haemonetics.gcs-web.com/investor-overview)
Leading position in Plasma with modern, integrated technology solutions

<table>
<thead>
<tr>
<th>Business Model</th>
<th>Product Portfolio</th>
<th>Market Lifecycle</th>
<th>Market Position</th>
<th>Competition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasmapheresis</strong></td>
<td><strong>Software</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital/Disposables</td>
<td>Software Solutions</td>
<td>NexSys PCS®/PCS®2</td>
<td>Growth</td>
<td>Fresenius Fenwal (Aurora), Other (OUS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MAK, homegrown</td>
</tr>
</tbody>
</table>

**NexSys PCS®**
Collection device

**NexLynk DMS®**
Donor management software

**Value-added software “apps”**
Plasma end market demand remains strong and HAE is prepared to support this opportunity

Robust growth in plasma-derived therapeutics

~8%
Est '15-'23 CAGR¹

~756
Registered clinical trials²

Pre-clin.
Recombinant IgG

Therapeutic alternatives viewed as early stage

PII
FcRn

Increased production capacity

~2X
Historical fractionation capacity³
(45M → 90M liters)

~9%
'13-'17 CAGR⁴
US plasma center collections

~12%
'13-'17 CAGR⁴
# of US plasma centers

HAE positioned to support growth

~50%
Increase in plasma collection disposables capacity

NexSys platform with Persona™ enables increase in plasma collection

2. clinicaltrials.gov 8/10/18 ClinicalTrials "plasma derived" search return
NexSys platform improves customer identified tangible value drivers

Plasma Yield
- Increased Plasma yield by 18-26ml per donation on average through YES® Technology¹

Productivity
- ~20% improvement in door to door efficiency²
- Increased labor effectiveness
- Business Optimization support
- 10% reduction in cost to collect a liter of plasma³

Quality and Compliance
- >91% reduction in key quality events (overdraws, documentation errors)²
- Bi-directional, paperless workflow helps eliminate errors and enforces compliance

Donor Experience
- Reduced donation times
- Increased donor engagement and satisfaction
- Improved staff responsiveness

1. Plasma yield enhancing solution; YES® Technology is available in the United States only
2. In-market results from NexSys PCS/NexLynk DMS implementations baselined versus Haemonetics PCS®2 device use, non bi-directionally integrated with Haemonetics DMS
3. Estimated based on internal data
The Persona™ Plasma Collection Solution Enables the new Persona Nomogram

Persona™ a proprietary integrated plasma collection solution built upon the NexSys PCS® platform, is the first and only donor-tailored solution clinically shown to yield +9% to 12%¹ more plasma per donation on average to maximize both cost-efficient output and patient impact.

1. Based on baseline device, software configuration, and donor population
The Persona™ Nomogram: core of the Persona™ Solution

1992 Simplified Nomogram

- Collect more from donors with higher body weight / BMI and lower hematocrit (low total plasma volume).
- Collect less from donors with lower body weight / BMI and higher hematocrit (high total plasma volume).

New Persona™ Nomogram

- Those with least to give
- Those with most to give

1. Based on a tailored collection target of 28.5% of total plasma volume.
2. “Results from IMPACT, a Randomized Controlled Trial of 23,137 Donations”. For more information about the clinical trial behind the Persona Plasma Collection Solution please click here.
Leading positions within three synergistic Hospital markets with state-of-the-art product offering

<table>
<thead>
<tr>
<th>Business Model</th>
<th>Product Portfolio</th>
<th>Market Lifecycle</th>
<th>Market Position</th>
<th>Competition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemostasis Management</td>
<td>Capital/Disposables</td>
<td>Developing</td>
<td>1</td>
<td>IL (ROTEM), Stago (HemaSonics)</td>
</tr>
<tr>
<td></td>
<td>TEG® 5000, TEG®6s &amp; TEG Manager, ClotPro</td>
<td>Mature</td>
<td>2</td>
<td>LivaNova, Fresenius, Medtronic</td>
</tr>
<tr>
<td>Cell Salvage</td>
<td>Capital/Disposables</td>
<td>Mature</td>
<td>2</td>
<td>Cerner, Mediware</td>
</tr>
<tr>
<td>Transfusion Management</td>
<td>Software Solutions</td>
<td>Developing</td>
<td>1</td>
<td>MSoft</td>
</tr>
<tr>
<td></td>
<td>SafeTrace Tx®</td>
<td>Mature</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BloodTrack®</td>
<td>Developing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

11 © 2020 Haemonetics Corporation
Strong market opportunity
TEG reinforces Hospital as a growth driver

HAE’s Hospital Near-term Market Opportunity in our Core Markets

Cell Salvage
- Share of voice:
  - CV Surgery
  - Trauma

Transfusion Management
- Next generation BBIS
- Smarter and safer BIMS

Hemostasis Management
- Standard of care and market growth
- Attractive core markets:
  - Interventional Cardiology
  - CV Surgery
  - Trauma
- Hospital growth platform

~$1.0B
~$500M
~$200M
~$300M

1. Annual disposables market only in core markets
2. HIMSS Logic Database, Internal Analysis & Calculations
3. Blood Bank Information System
4. Blood Inventory Management System
Three Blood Center portfolios that offer safe, reliable blood collection solutions

- **Apheresis**
  - Business Model: Capital/Disposables
  - Product Portfolio: MCS+ Suite, ACP-215
  - Market Lifecycle: Mature
  - Competition: Fresenius, Terumo

- **Whole Blood**
  - Business Model: Disposables
  - Product Portfolio: Manual Blood Collections and Filtration
  - Market Lifecycle: Mature
  - Competition: Fresenius, Terumo, Macopharma

ACP®215
MCS®+ 9000
Blood Center market remains challenging
Significant cash flow opportunity

Market:
• Decline in blood transfusion rates due to:
  • Decline in invasive surgeries
  • Improvements in BMP\(^1\)
  • Pharmaceuticals
• High-yield, multi-dose collections are becoming a new standard
• Tender-driven business creates pricing pressures (mostly OUS)

HAE Opportunity:
• Complexity reduction through:
  • Standardized technology
  • Optimized product portfolio
  • Reduced commercial footprint
• Customized pricing strategies
• Strategic resource allocation
• Improvements in cost of goods sold
• Focus on profitability and cash flow

© 2020 Haemonetics Corporation
Innovation Agenda to support long-term growth

<table>
<thead>
<tr>
<th>Plasma</th>
<th>Hospital</th>
<th>Blood Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater plasma collection</td>
<td>Broader indications for TEG®</td>
<td>Safer donations &amp; end products</td>
</tr>
<tr>
<td>Better donor engagement</td>
<td>Region specific innovation</td>
<td>Customized donor collections</td>
</tr>
<tr>
<td>Improved safety</td>
<td>Integrated software solutions</td>
<td>Increased product yield</td>
</tr>
</tbody>
</table>

VOC & Customer Engagements

Clinical & Real-world Evidence

Software & Digital Solutions
Capital allocation priorities to support organic and inorganic value creation

1. Organic business needs (R&D, S&M, CAPEX)

2. Inorganic growth opportunities (including M&A)

3. Share repurchases
Well-positioned to create long-term value

Our 5-year Turnaround plan

Accelerate growth
- NexSys PCS® +Persona™/ NexLynk DMS® roll-out
- Accelerated growth in Hospital
- Inorganic growth opportunities

Transform
- BU-centric, performance-driven culture
- Lean, improved operating model
- Complexity Reduction Initiative (CRI)

Stabilize
- Stabilize Blood Center
- Rationalize portfolio

Fast growing, innovative company that outpaces the market

FY17  FY19  FY21